Michael Gorin

Sep 26, 2024 | urologytimes.com | Michael Gorin

2 Commerce Drive Cranbury, NJ 08512

Sep 19, 2024 | urologytimes.com | Michael Gorin

The CLARIFY Trial Design and Objectives for PSMA ImagingMichael Gorin, MD discusses the impact of next-day imaging and the potential imaging improvements as physicians await the results of the CLARIFY trial.

Sep 19, 2024 | urologytimes.com | Michael Gorin

COBRA AND PROPELLER: Background and Results of Prior PSMA Imaging TrialsMichael Gorin, MD provides the background and results of two key imaging trials that reviewed the efficacy of this new copper-based agent.

Sep 12, 2024 | urologytimes.com | Michael Gorin

A medical expert discusses how emerging copper-based developments in PSMA imaging, particularly the 64Cu-SAR-bisPSMA agent, offer advancements in tumor detection and imaging logistics compared to traditional agents.

Sep 12, 2024 | urologytimes.com | Michael Gorin

PSMA PET Imaging: The Landscape and Current ChallengesA medical discusses how advancements in PSMA PET imaging, including the development of agents like 64Cu-SAR-bisPSMA, address current challenges in sensitivity and logistical issues, potentially enhancing tumor detection and patient outcomes.